Latest News and Press Releases

Dublin, April 10, 2025 (GLOBE NEWSWIRE) -- The "Antiviral Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to ...

Dublin, Nov. 01, 2024 (GLOBE NEWSWIRE) -- The "Antiviral Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering. ...

Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Global Oral Antiviral Market 2024 Edition: Market Size, Trends, Opportunities and Forecast by Drug Class, Indication, Distribution Channel, Region, By...

Dublin, Sept. 21, 2023 (GLOBE NEWSWIRE) -- ResearchAndMarkets.com announces a comprehensive analysis of the Oral Antiviral Market, projecting a promising CAGR of 2.1% from 2022 to 2031. The "Oral...

Portland, OR, April 03, 2023 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global oral antiviral market generated $35.21 billion in 2021, and is estimated to...

BOTHELL, Wash., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces highly favorable safety and tolerability results for its orally administered replication inhibitor...

CARLSBAD, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel oral antiviral drug...

CARLSBAD, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel...

CARLSBAD, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (Nasdaq: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel oral...

Phase 2 trial expected to enroll 210 patients at approximately 75 sites to evaluate antiviral activity, safety, and efficacy of PBI-0451 versus placebo Interim data from Phase 2 anticipated in Q1...